Table 4.
Topic | Task | Dataset | Model | Performance | Year | Ref. |
---|---|---|---|---|---|---|
Recurrence | Recurrence perdition of stage II CRC | Clinicopathological data of 350 patients after curative resection for stage II CRC | Nomogram | C-index: 0.585 in the validation set | 2020 | [88] |
Recurrence prediction of Stage IV CRC after tumor resection | EHR data from 999 patients of stage IV CRC | LR, DT, GB and LightGBM | LightGBM: AUC: 0.761 | 2020 | [89] | |
Recurrence prediction of local tumor | PET-CT images from 84 patients | CNN, Proportional hazards model | C-index: 0.64 | 2019 | [90] | |
Risk prediction of recurrence of gastrointestinal stromal tumor | Clinical data of 2560 patients | Proportional hazards, Non-linear model | AUC: 0.88 | 2012 | [91] | |
Recurrence perdition after surgery | Clinicopathological data of 1320 nonmetastatic CRC patients | NomogramCOX regression | C-index: 0.77 | 2008 | [92] | |
Survival | Genetic risk factors Identification | National Center for Biotechnology Information Gene Expression Omnibus | GSEA, PPI network, Cox Proportional Hazard regression | 4 sub-networks and 8 hub genes as potential therapeutic targets | 2021 | [93] |
Prognostic prediction for stage III CRC | Clinicopathological data of 215 patients | CNN, GB | HR: 8.976 and 10.273 | 2020 | [94] | |
Outcome prediction | 12,000,000 HE images | CNN | HR: 3.84 and 3.04 with established prognostic markers | 2020 | [95] | |
Survival prediction | 7180 HE images of 25 patients | CNN | Nine-class accuracy: >94% | 2019 | [96] | |
Survival prediction | PET-CT images of 84 patients | CNN, proportional hazards model | C-index: 0.64 | 2019 | [90] | |
Outcome prediction, and remaining lifespan prediction | SEER | tree-based ensemble model | Accuracy: 0.7069, Sensitivity: 0.8452, Specificity: 0.66 |
2019 | [97] | |
Outcome prediction | 75 WSIs from stage I and II CRC patients with surgical resection | CNN | F1: 0.67 | 2019 | [98] | |
Outcome prediction | EHR data of 58,152 patients | CNN | AUC: 0.922, Sensitivity: 0.837, specificity: 0.867, PPV: 0.532 | 2019 | [99] | |
Prediction of Stages and Survival Period | Clinicopathological data of 4021 patients | RF, SVM, LR, MLP, KNN, and AdaBoost | RF: F-measure: 0.89, Accuracy: 84%, AUC: 0.82 ± 0.10 | 2019 | [100] | |
1/2/5 years Survival prediction | SEER data | DNN | AUC: 0.87 | 2019 | [101] | |
Outcome prediction | Digitized HE tumor tissue microarray samples of 420 patients | CNN, LSTM | LSTM: AUC: 0.69, histological grade AUC: 0.57, the visual risk score AUC: 0.58 | 2018 | [102] | |
5-year survival prediction | EHR data of 1127 CRC patients | Ensemble (bagging and voting) classifier | Ensemble voting model AUC: 0.96 | 2017 | [103] | |
5-year survival prediction | EHR data of 334,583 cases from Robert Koch Institute | SVM, LR, NB, DT, KNN, LR, NN, RF | Average accuracy of the clinicians: 59%, ML: 67.7% | 2015 | [104] |